Pliant Therapeutics, Inc.
PLRX
$1.19
$0.043.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.56% | -7.93% | -3.01% | 0.49% | 1.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.66% | -16.15% | 5.83% | 20.66% | 22.96% |
| Operating Income | 32.66% | 16.15% | -5.83% | -20.81% | -24.01% |
| Income Before Tax | 28.99% | 12.98% | -11.63% | -28.56% | -30.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.99% | 12.98% | -11.63% | -28.56% | -30.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.99% | 12.98% | -11.63% | -28.56% | -30.35% |
| EBIT | 32.66% | 16.15% | -5.83% | -20.81% | -24.01% |
| EBITDA | 32.78% | 16.15% | -5.96% | -20.93% | -24.10% |
| EPS Basic | 29.90% | 14.19% | -9.87% | -26.35% | -26.44% |
| Normalized Basic EPS | 31.98% | 14.14% | -9.88% | -26.36% | -26.44% |
| EPS Diluted | 29.90% | 14.19% | -9.87% | -26.35% | -26.44% |
| Normalized Diluted EPS | 31.98% | 14.14% | -9.88% | -26.36% | -26.44% |
| Average Basic Shares Outstanding | 1.37% | 1.52% | 1.68% | 1.78% | 3.12% |
| Average Diluted Shares Outstanding | 1.37% | 1.52% | 1.68% | 1.78% | 3.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |